rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2014-251-253rsp-1935Research ArticleМЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙINTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASESСтратегия «Лечение до достижения цели» при спондилоартритах«TREAT-TO-TARGET» (T2T) STRATEGY IN SPONDYLOARTHRITISЭрдесШ. Ф.ErdesSh. F.erdex@irramn.ruФГБУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой» РАН, Москва, РоссияРоссияNasonova Research Institute of Rheumatology, Moscow, RussiaRussian Federation201420062014523№3 (2014)251253Copyright © Эрдес Ш.Ф., 20142014Эрдес Ш.Ф.Erdes S.F.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/1935

В статье коротко представлены некоторые особенности разработки стратегии «Лечение до достижения цели» для спондилоартритов (СпА). Коротко описаны причины некоторых несоответствий между современной концепцией СпА и названием статьи, где представлена программа. Приведен полный русский перевод стра- тегии Т2Т при данном заболевании и отмечены основные сложности ее разработки. Показано, что главной целью терапии является достижение клинической ремиссии или низкой активности заболевания, однако окончательной дефиниции данного состояния еще нет. 

The paper briefly presents some specific characteristics of development of a treat-to-target (T2T) strategy for spondy- loarthritis (SA). The reasons for some inconsistencies between the current concept of SA and the name of the paper presenting the program are described shortly. A complete Russian translation of the T2T strategy for this disease is given and major problems in its development are outlined. The main goal of therapy is shown to achieve clinical remission or low disease activity; however, there has not yet been a final definition of this condition. 

стратегия «Лечение до достижения цели»спондилоартритыпсориатический артританкило- зирующий спондилит.treat-to-targetspondyloarthritispsoriatic arthritisankylosing spondylitis.ReferencesRyden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7. DOI: 10.1136/ard.2009.123919. Epub 2010 Mar 9.Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7. DOI: 10.1136/ard.2009.123919. Epub 2010 Mar 9.Mosca M, Boumpas DT, Bruce IN, et al. Treat-to-target in sys- temic lupus erythematosus: where are we today? Clin Exp Rheumatol. 2012;30(4 Suppl 73):S112–5.Mosca M, Boumpas DT, Bruce IN, et al. Treat-to-target in sys- temic lupus erythematosus: where are we today? Clin Exp Rheumatol. 2012;30(4 Suppl 73):S112–5.Baeten D, Breban M, Lories R, et al. Are spondylarthritides relat- ed but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum. 2013;65(1):12–20. DOI: 10.1002/art.37829.Baeten D, Breban M, Lories R, et al. Are spondylarthritides relat- ed but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum. 2013;65(1):12–20. DOI: 10.1002/art.37829.Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to tar- get: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-203419.Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to tar- get: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-203419.Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238–42. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-203860.Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238–42. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-203860.Smolen JS, Braun J, Dougados M, et al. Treat-to-target recom- mendations for spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis: a consensus of an international task force. Ann Rheum Dis. 2013;72 Suppl 3:OP0110.Smolen JS, Braun J, Dougados M, et al. Treat-to-target recom- mendations for spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis: a consensus of an international task force. Ann Rheum Dis. 2013;72 Suppl 3:OP0110.

The authors declare that there are no conflicts of interest present.